Obesity Clinical Trial
Official title:
Role of Autophagy and Inflammasome in the Pathophysiology of Obesity: Effect of Weight Loss and Potential Therapeutic Implications
The main aim of this project is to determine the implication of autophagy and inflammasome in the pathogenesis of obesity and related comorbidities, and to explore in depth the mechanisms associated with the activation of immune cells leading early stages of the atherosclerotic process and metabolic disease. The hypothesis of the present study is that weight loss mediated by Roux-en-Y gastric bypass (RYGB) improves the protein expression of markers of autophagy and inflammation within immune cells. Moreover, the investigators will explore the association of these mechanisms with the mitochondrial function and dynamics, Endoplasmic Reticulum (ER) stress an intracellular nutritional status of leukocytes (measured by fluorescence microscopy and western blot). Further, the potential relationship between changes in the mentioned intracellular pathways and systemic pathological mechanisms including oxidative stress, inflammation and glucose and lipid metabolism will be explored. Hence, serum carbonylated proteins, myeloperoxidase (MPO) levels, antioxidant enzymatic activities including SOD (Superoxide dismutase) and catalase, circulating cytokines, and glucose and lipid metabolism parameters will be evaluated in a cohort of obese subjects before and 12 months after RYGB intervention.
Status | Completed |
Enrollment | 45 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Body Mass Index (BMI) = 30 kg/m^2 - duration of obesity over 5 years Exclusion Criteria: - history of drug abuse - pregnancy or lactation - neoplastic disease - severe renal/hepatic disease - history of cardiovascular disease - chronic inflammatory disease - secondary cause for obesity (hypothyroidism, Cushing's syndrome) |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Doctor Peset | Valencia |
Lead Sponsor | Collaborator |
---|---|
Milagros Rocha Barajas | Hospital Universitario Doctor Peset, Instituto de Salud Carlos III |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the protein expression of autophagy markers in leukocytes 12 months after the RYGB intervention | Relative expression of intracellular proteins related autophagy/mitophagy mechanisms (Beclin 1, ATG5, LC3II/I, NRB1, PINK1, MIEAP) assessed by western blot and normalized to the loading control protein. | 12 months | |
Primary | Changes in the relative protein expression of inflammatory mediators in leukocytes 12 months after the RYGB intervention | Relative expression of intracellular proteins related to inflammatory pathways (MCP1, NF-kB) assessed by western blot and normalized to the loading control protein. | 12 months | |
Secondary | Changes in the protein expression of markers of mitochondrial dynamics and function in leukocytes 12 months after the RYGB intervention. | Relative expression of proteins related to mitochondrial dynamics and function (OPA1, FIS1, MFN1, DRP1, MFN2, OXPHOS Complex, MTTFA, PGC1a, NRF1, BNIP3) assessed by western blot and normalized to the loading control protein. Changes in mitochondrial membrane potential of leukocytes after the intervention assessed by fluorescence dye TMRM. | 12 months | |
Secondary | Changes in the protein expression of markers of nutrient sensing and ER stress in leukocytes 12 months after the RYGB intervention. | Relative expression of proteins related to nutritional status, metabolism and Endoplasmic Reticulum (ER) stress (AMPK, SIRT1, ATF6, CHOP) assessed by western blot and normalized to the loading control protein. | 12 months | |
Secondary | Changes in superoxide production 12 months after the RYGB intervention. | Evaluation of superoxide production in leukocytes by means of fluorescence dye (Relative Fluorescence Units) as contributor to pro-oxidant processes. | 12 months | |
Secondary | Changes in serum MPO levels 12 months after the RYGB intervention. | Evaluation of serum levels of the prooxidant MPO by immunoassay ELISA (ng/mL) as contributor to pro-oxidant and pro-inflammatory processes. | 12 months | |
Secondary | Changes in protein carbonylation in serum 12 months after the RYGB intervention. | Evaluation of carbonyl groups in serum proteins by means of immunoassay ELISA (nmol/mg protein) as a marker of systemic oxidative damage. | 12 months | |
Secondary | Changes in serum SOD enzymatic activity 12 months after the RYGB intervention. | Evaluation of SOD enzymatic activity in serum (nmol/min/mL) as part of the systemic antioxidant defense system. | 12 months | |
Secondary | Changes in serum catalase enzymatic activity 12 months after the RYGB intervention. | Evaluation of catalase enzymatic activity in serum (nmol/min/mL) as part of the systemic antioxidant defense system. | 12 months | |
Secondary | Effect of the RYGB on body weight | Changes in the body weight (kg) of patients 12 months after the RYGB intervention determined with an electronic scale | 12 months | |
Secondary | Effect of the RYGB on Body Mass Index (BMI) | Changes in the BMI (kg/m^2) of patients 12 months after the RYGB intervention, measure by the formula: weight (kg) / [height (m)]^2 | 12 months | |
Secondary | Effect of the RYGB on blood pressure | Changes in Systolic/Diastolic Blood Pressure levels (SBP/DBP) (mmHg) measured with a sphygmomanometer | 12 months | |
Secondary | Effect of the RYGB on fasting Glucose levels | Changes in fasting Glucose (mg/dL) of patients 12 months after the RYGB intervention, as a marker of glucose metabolism | 12 months | |
Secondary | Effect of the RYGB on fasting Insulin levels | Changes in fasting Insulin (µU/mL) of patients 12 months after the RYGB intervention, as a marker of glucose metabolism | 12 months | |
Secondary | Effect of the RYGB on Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index | Changes in HOMA-IR Index of patients 12 months after the RYGB intervention, measured with the formula: [Fasting Glucose (mg/dL) x Fasting Insulin (µU/mL)]/405, as a marker of glucose metabolism | 12 months | |
Secondary | Effect of the RYGB on glycated hemoglobin (HbA1c) | Changes in HbA1c (%) of patients 12 months after the RYGB intervention, as a marker of glucose metabolism | 12 months | |
Secondary | Effect of the RYGB on Total Cholesterol (TC) | Changes in TC (mg/dL) of patients 12 months after the RYGB intervention, as a marker of the lipid profile | 12 months | |
Secondary | Effect of the RYGB on High Density Lipoprotein Cholesterol (HDLc) levels | Changes in HDLc (mg/dL) of patients 12 months after the RYGB intervention, as a marker of the lipid profile | 12 months | |
Secondary | Effect of the RYGB on Low Density Lipoprotein Cholesterol (LDLc) levels | Changes in LDLc (mg/dL) of patients 12 months after the RYGB intervention, as a marker of the lipid profile | 12 months | |
Secondary | Effect of the RYGB on Triglyceride (TG) levels | Changes in TG (mg/dL) of patients 12 months after the RYGB intervention, as a marker of the lipid profile | 12 months | |
Secondary | Effect of the RYGB on high sensitivity C-Reactive Protein (hsCRP) levels | Changes in hsCRP (mg/L) of patients 12 months after the RYGB intervention, as a marker of systemic inflammation | 12 months | |
Secondary | Effect of the RYGB on Interleukin-6 (IL6) levels | Changes in IL6 (pg/mL) of patients 12 months after the RYGB intervention, as a marker of systemic inflammation | 12 months | |
Secondary | Effect of the RYGB on Interleukin-1 ß (IL1ß) levels | Changes in IL1ß (pg/mL) of patients 12 months after the RYGB intervention, as a marker of systemic inflammation | 12 months | |
Secondary | Remission rate for pathologies related to metabolic syndrome 12 months after RYGB intervention | Percentage of cases of remission for hypertension, hyperlipidemia and type 2 diabetes (T2D) after the intervention. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |